Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLJT-002
- Development stage
- Preclinical
- Lead developer
- Panlong Pharmaceutical
- Modality
- Small Molecules
01
Overview
PLJT-002 is an investigational small molecule drug candidate being developed by Shaanxi Panlong Pharmaceutical Group (Panlong Pharma) for the treatment of orthopedic pain. As of early 2025, the asset is in the IND-enabling (Investigational New Drug) phase of development. Panlong Pharma, a company with a strong historical focus on orthopedic traditional Chinese medicine and modern formulations, is utilizing PLJT-002 to expand its innovative pipeline into targeted small molecule therapeutics. While the specific biological target and mechanism of action have not been publicly disclosed, the drug is intended to address clinical needs in musculoskeletal and bone-related pain management.
Beyond the preview
Go deeper on PLJT-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLJT-002.